Drug Approval | December 27, 2023
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
The product is expected to be launched in December 2023
The product is expected to be launched in December 2023
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Receives registration of Valganciclovir powder for oral solution in Germany
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
This product will be manufactured at Lupin's Nagpur facility in India
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
The product is being launched in August 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Subscribe To Our Newsletter & Stay Updated
